Chen W, Liu Y, Li Y, et al. - Researchers assessed if sacubitril/valsartan could result in improved cardiac function among Chinese patients suffering from heart failure with reduced ejection fraction (HFrEF) in a tertiary hospital in China. A total of 100 consecutive patients (73% male) with HFrEF receiving sacubitril/valsartan were included. A significant improvement in New York Heart Association classification was conferred by this treatment, and a significant reduction in median N-terminal pro-B-type natriuretic peptides level from 3003 pg/mL to 2039 pg/mL was also noted. An increase in mean left ventricular ejection fraction from 31 ± 6% to 38 ± 10% and decrease in median left ventricular end-diastolic diameter from 63 mm to 60 mm was observed. Findings showed a pronounced improvement of cardiac function was conferred by sacubitril/valsartan treatment in Chinese patients with HFrEF, however, this treatment might be prone to a reduction in blood pressure and deterioration in renal function.